KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Receivables (2016 - 2026)

Medtronic's Receivables history spans 13 years, with the latest figure at $6.4 billion for Q1 2026.

  • For Q1 2026, Receivables rose 3.99% year-over-year to $6.4 billion; the TTM value through Jan 2026 reached $6.4 billion, up 3.99%, while the annual FY2025 figure was $6.5 billion, 6.32% up from the prior year.
  • Receivables for Q1 2026 was $6.4 billion at Medtronic, roughly flat from $6.4 billion in the prior quarter.
  • Across five years, Receivables topped out at $6.5 billion in Q2 2025 and bottomed at $5.3 billion in Q3 2022.
  • The 5-year median for Receivables is $6.0 billion (2023), against an average of $6.0 billion.
  • The largest annual shift saw Receivables fell 2.26% in 2022 before it grew 9.38% in 2023.
  • A 5-year view of Receivables shows it stood at $5.6 billion in 2022, then increased by 5.47% to $5.9 billion in 2023, then rose by 5.49% to $6.3 billion in 2024, then increased by 2.06% to $6.4 billion in 2025, then decreased by 0.47% to $6.4 billion in 2026.
  • Per Business Quant, the three most recent readings for MDT's Receivables are $6.4 billion (Q1 2026), $6.4 billion (Q4 2025), and $6.3 billion (Q3 2025).